2.80
Editas Medicine Inc stock is traded at $2.80, with a volume of 1.46M.
It is up +2.56% in the last 24 hours and down -16.67% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
See More
Previous Close:
$2.73
Open:
$2.74
24h Volume:
1.46M
Relative Volume:
0.59
Market Cap:
$251.78M
Revenue:
$32.31M
Net Income/Loss:
$-237.09M
P/E Ratio:
-0.9722
EPS:
-2.88
Net Cash Flow:
$-219.11M
1W Performance:
-7.59%
1M Performance:
-16.67%
6M Performance:
+45.83%
1Y Performance:
-26.12%
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
EDIT
Editas Medicine Inc
|
2.80 | 245.48M | 32.31M | -237.09M | -219.11M | -2.88 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-28-25 | Initiated | H.C. Wainwright | Buy |
Dec-16-24 | Downgrade | JP Morgan | Neutral → Underweight |
Dec-13-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Dec-13-24 | Downgrade | Stifel | Buy → Hold |
Dec-13-24 | Downgrade | Truist | Buy → Hold |
Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Nov-25-24 | Downgrade | BofA Securities | Buy → Underperform |
Nov-06-24 | Upgrade | Evercore ISI | In-line → Outperform |
Nov-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Sep-29-23 | Upgrade | Stifel | Hold → Buy |
Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Dec-13-22 | Initiated | Citigroup | Neutral |
Dec-06-22 | Resumed | Credit Suisse | Neutral |
Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
Sep-29-22 | Initiated | BofA Securities | Neutral |
Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
Sep-24-21 | Initiated | Stifel | Hold |
Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
Aug-09-21 | Upgrade | Truist | Hold → Buy |
Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
Jun-04-21 | Resumed | Robert W. Baird | Outperform |
May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
Apr-16-21 | Initiated | Goldman | Sell |
Mar-22-21 | Initiated | Credit Suisse | Outperform |
Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
Feb-26-21 | Downgrade | Truist | Buy → Hold |
Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Nov-03-20 | Initiated | Robert W. Baird | Underperform |
Jun-18-20 | Resumed | SunTrust | Buy |
Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Oct-10-18 | Initiated | Guggenheim | Neutral |
Sep-21-18 | Initiated | Raymond James | Outperform |
May-15-18 | Reiterated | Chardan Capital Markets | Buy |
Feb-13-18 | Initiated | CLSA | Underperform |
Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
Jul-14-17 | Initiated | SunTrust | Hold |
Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
Jun-02-16 | Initiated | Jefferies | Hold |
Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
Feb-29-16 | Initiated | JP Morgan | Neutral |
Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Editas Medicine (NASDAQ:EDIT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Editas Medicine Inc. Moves Into Overbought Range Analysts CautiousPrice Action & Stepwise Swing Trade Plans - beatles.ru
Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results - MarketBeat
Editas Medicine (NASDAQ:EDIT) Price Target Raised to $6.00 at Robert W. Baird - MarketBeat
Short interest data insights for Editas Medicine Inc.2025 Market Trends & Low Risk High Win Rate Stock Picks - Newser
Intraday pattern recognizer results for Editas Medicine Inc.July 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - Newser
How to recover losses in Editas Medicine Inc. stockPortfolio Growth Summary & Low Drawdown Trading Techniques - Newser
Ranking Editas Medicine Inc. among high performing stocks via toolsJuly 2025 Technicals & Fast Moving Trade Plans - Newser
How to build a custom watchlist for Editas Medicine Inc.Weekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser
Trend analysis for Editas Medicine Inc. this weekWeekly Trend Recap & Comprehensive Market Scan Insights - Newser
Editas Medicine Inc. Faces Significant Business Risks: Key Factors for Investors to Watch - MSN
What makes Editas Medicine Inc. stock price move sharplyTrend Reversal & High Accuracy Buy Signal Tips - Newser
Is Editas Medicine Inc. showing signs of accumulationMarket Growth Review & High Accuracy Buy Signal Tips - Newser
HC Wainwright Boosts Editas Medicine Price Target to $5.00, Analysts Predict 22.47% Upside - AInvest
Editas Medicine's Q2 Earnings Boost Stock Price 34% Amid Plans to Nominate First In Vivo Development Candidate in September - AInvest
Editas Medicine (NASDAQ:EDIT) Downgraded to Sell Rating by Wall Street Zen - Defense World
Why Editas Medicine Inc. stock attracts strong analyst attentionJuly 2025 Pullbacks & Free Verified High Yield Trade Plans - sundaytimes.kr
Editas Medicine: Strategic Position Balances Cautious Development and Financial Stability - TipRanks
What drives Editas Medicine Inc.’s stock priceProduct Launch & Daily Technical Stock Forecast Reports - thegnnews.com
Why Editas Medicine Stock Was Skyrocketing This Week - AOL.com
H.C. Wainwright raises Editas Medicine stock price target to $5 on pipeline progress - Investing.com Canada
Editas Medicine: HC Wainwright Raises PT to $5, Maintains Buy Rating - AInvest
Robert W. Baird Forecasts Strong Price Appreciation for Editas Medicine (NASDAQ:EDIT) Stock - Defense World
How Interest Rate Changes Impact Editas Medicine Inc. Stock PerformanceMarket Movement Recap & Daily Profit Focused Stock Screening - Newser
Editas Medicine Inc. Rebound Backed by Sentiment Shift2025 Price Action Summary & Consistent Income Trade Recommendations - sundaytimes.kr
Applications Of Genetic Engineering Market is Booming Worldwide | Editas Medicine , Intellia Therapeutics - newstrail.com
Editas Medicine Inc. Pullback Analyzed — Is It Time to Exit2025 Sector Review & Weekly Chart Analysis and Trade Guides - sundaytimes.kr
Editas Medicine Reports Q2 2025 Progress and Financials - TipRanks
Editas Medicine’s SWOT analysis: gene editing stock faces challenges, opportunities - Investing.com
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $3 to $6 - 富途牛牛
Editas Medicine shares surge 28.87% intraday after strong Q2 earnings and positive analyst ratings. - AInvest
Editas Medicine Surges 34% on Q2 Momentum and Strategic Milestones – What’s Fueling the Biotech Rally? - AInvest
Can Editas Medicine Inc. Regain Momentum After BreakdownQuarterly Profit Review & Precise Buy Zone Identification - 선데이타임즈
Baird raises Editas Medicine stock price target to $6 on pipeline progress - Investing.com Nigeria
Editas: Q2 Earnings Snapshot - Greenwich Time
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates - MSN
What high frequency data says about Editas Medicine Inc.2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - Newser
Editas Medicine 2025 Q2 Earnings Narrows Losses Amid Revenue Surge - AInvest
Editas Medicine Announces Second Quarter 2025 Results and Business Updates - GlobeNewswire
Editas Medicine's Q2 Performance: Assessing Progress Amid Financial Challenges - AInvest
Editas Medicine Misses Expectations But Stays Focused On The Future - Finimize
Editas Medicine earnings missed by $0.23, revenue topped estimates - Investing.com Canada
Editas Medicine Inc Q2 2025 Earnings: Revenue Soars to $3.6M, Beating Estimates; EPS Misses at -$0.63 - GuruFocus
Editas Medicine posts Q2 net loss of $53.2 mln - MarketScreener
Editas Medicine Q2 2025: On track to file IND by mid-2026, proof-of-concept by year-end. - AInvest
Editas Medicine Reports Q2 2025 Results, Advances Gene Editing Programs - AInvest
Editas Medicine narrows losses as Bristol Myers Squibb partnership hits key milestone - Stock Titan
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Editas Medicine Inc Stock (EDIT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER |
Jul 31 '25 |
Sale |
2.49 |
5,121 |
12,757 |
64,398 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):